Protocol Ledger

NCT07563881 · Phase III · RECRUITING

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Interventional Phase III clinical trial protocol NCT07563881 sponsored by Rapport Therapeutics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-05 Enrollment: 333 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07563881
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)333 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07563881
Protocol FieldVerified Registry Value
NCT IdentifierNCT07563881
Consolidated Lead SponsorRapport Therapeutics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment333 participants (ESTIMATED)
Registered Start Date2026-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI